Temsirolimus
- Generic Name
- Temsirolimus
- Brand Names
- Torisel
- Drug Type
- Small Molecule
- Chemical Formula
- C56H87NO16
- CAS Number
- 162635-04-3
- Unique Ingredient Identifier
- 624KN6GM2T
- Background
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
- Indication
For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
- Associated Conditions
- Advanced Renal Cell Carcinoma
- Associated Therapies
- -
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT01625156
- Locations
- 🇺🇸
Wisconsin Clinical Cancer Center, Milwaukee, Wisconsin, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT01614795
- Locations
- 🇺🇸
Stony Brook University Medical Center, Stony Brook, New York, United States
🇺🇸Children's Hospital Medical Center of Akron, Akron, Ohio, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2023-07-27
- Target Recruit Count
- 16
- Registration Number
- NCT01614197
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States
🇺🇸Lurie Children's Hospital, Chicago, Illinois, United States
Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 33
- Registration Number
- NCT01611116
- Locations
- 🇩🇪
Charité University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany
🇩🇪University Hospital Dresden, Dresden, Germany
🇩🇪University Hospital Erlangen, Erlangen, Germany
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT01596140
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Temsirolimus as Second-line Therapy in HCC
- Conditions
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- University of Tennessee Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT01567930
- Locations
- 🇺🇸
Boston Baskin Cancer Foundation, Memphis, Tennessee, United States
Bevacizumab and Temsirolimus Alone or in Combination with Valproic Acid or Cetuximab in Treating Patients with Advanced or Metastatic Malignancy or Other Benign Disease
- Conditions
- Interventions
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 155
- Registration Number
- NCT01552434
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT01548482
- Locations
- 🇨🇦
BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Cristiana Sessa
- Target Recruit Count
- 25
- Registration Number
- NCT01535989
- Locations
- 🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Ticino, Switzerland
🇨🇭InselSpital, Universitätsspital Bern, Bern, Switzerland
🇨🇭Kantonsspital St.Gallen, San Gallen, Switzerland
Temsirolimus in Combination with Metformin in Patients with Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 87
- Registration Number
- NCT01529593
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.